Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products primarily in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, and respiratory diseases. It provides consumer healthcare products, such as condoms, pregnancy detection kits, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. The company offers its products primarily under the Manforce, Prega News, Unwanted-72, Gas-O-Fas, Health OK, and AcneStar brand names. In addition, it engages in the trading and exporting of pharmaceutical and health care products; manufacturing of packing materials ayurvedic products, packing materials, bulk drugs, and consumer goods; real estate, leasing, and hospitality businesses; and provision of IT services. The company was incorporated in 1991 and is based in New Delhi, India.

Revenue projections:

Revenue projections for MANKIND
Revenue projections for MANKIND

Mankind Pharma Limited's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.

Financial Ratios:

currentRatio 1.143000
forwardPE 34.890285
debtToEquity 53.892000
earningsGrowth -0.240000
revenueGrowth 0.202000
grossMargins 0.697820
operatingMargins 0.189200
trailingEps 42.550000
forwardEps 61.700000

With a current ratio 1.143, MANKIND demonstrates the ability to service its short-term debt without difficulty. The company's strong cash reserves and current assets ensure that it can meet its liabilities, reflecting financial stability and healthy liquidity.
MANKIND's low growth in earnings and revenue indicates a potential decline in profits. This suggests that the company could be facing financial challenges, making it harder to sustain its current profit margins.
MANKIND's negative gross and operating margins highlight potential financial struggles, as the company is not covering its production or operational expenses. This could lead to broader concerns about its ability to achieve profitability.
Mankind Pharma Limited's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that Mankind Pharma Limited's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.

Price projections:

Price projections for MANKIND
Price projections for MANKIND

Mankind Pharma Limited's price has continuously remained near the lower end of analysts' projections, indicating that it may be facing challenges in meeting market expectations. This trend raises concerns about the company's future growth trajectory.

Recommendation changes over time:

Recommendations trend for MANKIND
Recommendations trend for MANKIND


Analysts are favoring Mankind Pharma Limited with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider Mankind Pharma Limited as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.